KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC

Bookmark and Share
Published: 21 Oct 2018
Views: 1505
Dr Roy S. Herbst - Yale Cancer Centre, New Haven, USA

Dr Roy S. Herbst talks to ecancer at ESMO 2018 about the latest from the KEYNOTE-10 trial for non small cell lung cancer.

He discussed the latest data from this trial, noting the improved 3 year survival rate with patients expressing higher levels of PD-L1.

Among patients who relapsed, he also reports responses among those retreated with pembrolizumab, and considers what it may mean for treatment options in the refractory setting.

For more lung cancer news, watch Dr Enriqueta Felip summarise lung highlights from ESMO 2018 here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.